Department of Oncology and Rheumatology, Saarland University Medical School, D-66421 Homburg, Germany.
Clin Exp Rheumatol. 2012 Jan-Feb;30(1):45-50. Epub 2012 Mar 6.
Psoriatic arthritis (PsA) may progress to joint damage. Determining clinical predictors of joint damage assessed by radiography is important. The aim of this study was to determine clinical factors as possible predictors for radiological damage in hands and feet of PsA patients with a 12-month follow-up.
We conducted a retrospective study on 53 PsA patients who were taking disease-modifying anti-rheumatic drugs (DMARDs) and/or tumour necrosis factor (TNF)-alpha-blockers at a fixed dosage. The patients were observed in 118 follow-up visits (intervals of 12 months ± 3 months), according to a clinical and radiological protocol which included the documentation of the number of swollen and tender joints in hands and feet, the applied therapy, psoriasis, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and global health assessment. Outcome was defined as radiographic damage of hands and feet (Ratingen score). For the statistical analysis the Chi-Square test for 2x2 crosstables (with Fisher's correction, as required) was used.
Progressive radiological damage was more frequent among patients with an increasing swollen joint count (8 of 26 visits; 30.8%) than among those with a stable or decreased number of swollen joints (5 of 89 visits; 5.6%; p=0.001). The analysis of the patients stratified into the different treatment modalities resulted in a significant higher rate of radiological progress (20.8%) in patients on DMARD therapy compared with TNF-alpha blocking agents (0%) (p=0.009).
During a 12-month follow-up of PsA patients, an increasing number of swollen joints heralds progression of radiological damage. TNF-alpha-blocker therapy appears to be superior to DMARDs in the protection from radiological progress.
银屑病关节炎(PsA)可能会进展为关节损伤。确定影像学评估的关节损伤的临床预测因素很重要。本研究旨在确定具有 12 个月随访的 PsA 患者手部和足部影像学损伤的可能预测因素。
我们对 53 名正在服用疾病修饰抗风湿药物(DMARDs)和/或肿瘤坏死因子(TNF)-α 阻滞剂的固定剂量的 PsA 患者进行了回顾性研究。根据包括记录手部和足部肿胀和压痛关节数、应用治疗、银屑病、红细胞沉降率(ESR)、C 反应蛋白(CRP)和总体健康评估的临床和放射学方案,对患者进行了 118 次随访(12 个月±3 个月的间隔)。结果定义为手部和足部的放射学损伤(Ratingen 评分)。统计分析采用 2x2 交叉表的卡方检验(需要时采用 Fisher 校正)。
肿胀关节计数增加的患者中,进展性放射学损伤更为常见(26 次就诊中的 8 次;30.8%),而肿胀关节数稳定或减少的患者中(89 次就诊中的 5 次;5.6%;p=0.001)。对不同治疗方式的患者进行分层分析后,DMARD 治疗组的放射学进展率(20.8%)显著高于 TNF-α 阻滞剂组(0%)(p=0.009)。
在 PsA 患者的 12 个月随访期间,肿胀关节数的增加预示着放射学损伤的进展。TNF-α 阻滞剂治疗似乎优于 DMARDs ,能更好地防止放射学进展。